Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients

European Journal of Cancer

Volumn 34, Issue 11, 1998, Pages 1715-1720

  Sakata, Y ^a   Ohtsu, A ^b   Horikoshi, N ^c   Sugimachi, K ^d   Mitachi, Y ^e   Taguchi, T ^f  

^a AOMORI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c CANCER INSTITUTE HOSPITAL   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e Sendai Kosei Hospital   (Japan)

^f Japan Soc for Cancer Chemotherapy   (Japan)

Author keywords

Chemotherapy; Fluoropyrimidine; Gastric cancer; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE; FLUOROURACIL; TEGAFUR;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; FEMALE; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; STOMACH CANCER; STOMATITIS; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXONIC ACID; PYRIDINES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TEGAFUR; TREATMENT OUTCOME;

EID: 0032189218     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00211-1     Document Type: Article

References (30)

1. 1. Kelsen DP. Cancer of the Stomach, Cancer, Principles and Practice of Oncology, 4th edn. Philadelphia, J.B. Lippincott, 1993, 838-848.
2. 2. Wils J. The treatment of advanced gastric cancer. Semin Oncol 1996, 23, 397-406.
3. 3. Sakata Y, Suzuki H. Do we have a strategy for gastrointestinal cancers at present and in the future? Cancer Chemotherapy, 10. Tokyo, Japan, Excerpta Medica, 1995, 169-180.
4. 4. Moynihan T, Hansen R, Anderson T, et al. Continuous 5-fluorouracil infusion in advanced gastric carcinoma. Am J Clin Oncol 1988, 11, 461-464.
5. 5. Spicer DV, Ardalan B, Daniels JR, et al. Re-evaluation of the maximum tolerated dose of continuous venous infusion of 5-fluorouracil with pharmacokinetics. Cancer Res 1988, 48, 459-461.
6. 6. Heggie GD, Sommadossi JP, Diasio RB, et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987, 47, 2203-2206.
7. 7. Zhang R, Lu Z, Diasio RB, et al. Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms ofpyrimidine enzymes. Cancer Res 1993, 53, 2816-2822.
8. 8. Beck A, Etienne MC, Milano G, et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 1994, 30A, 1517-1522.
9. 9. Houghton JA, Houghton PJ, Wooten RS. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine and 5-fluoro-2′-deoxyuridine. Cancer Res 1979, 39, 2406-2413.
10. 10. Shirasaka T, Nakano K, Fukushima M, et al. Antitumor activity of 1M tegaful-0.4M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996, 56, 2602-2606.
11. 11. Shirasaka T, Shimamoto Y, Fukushima M, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anti-Cancer Drugs 1996, 7, 548-557.
12. 12. Takechi T, Nakano K, Shirasaka T, et al. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 1997, 39, 205-211.
13. 13. Tatsumi K, Fukushima M, Shirasaka T, et al. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res (Gann) 1987, 78, 748-755.
14. 14. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993, 53, 4004-4009.
15. 15. Taguchi T, Inuyama Y, Kanamaru R, et al. Phase I study of S-1, Jpn J Cancer Chemother 1997 24, 2253-2264 (in Japanese with English Abstract).
16. 16. Horikoshi N, Mitachi Y, Sakata Y, et al. S-1, new oral fluoropyrimidine is very active in patients with advanced gastric cancer (early phase II study). Proc Am Soc Clin Oncol 1996, 15, 466.
17. 17. Japan Society for Cancer Therapy. Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther 1993, 28, 101-130.
18. 18. Japanese Research Society for Gastric Cancer. Response assessment of chemotherapy for gastric carcinoma. Japanese Classification of Gastric Carcinoma, 1st English edn. Tokyo, Kanehara, 1995, 90-104.
19. 19. Kambe M, Wakui A, Nakao I, et al. A late phase II study of irinotecan (CPT-11) in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 1993, 12, 584.
20. ™) in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer 1994, 70, 380-383.
21. 21. Wils JA, Klein HO, Wagener DJT, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - a step ahead in the treatment of advanced gastric cancer: a trial of the EORTC Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991, 9, 827-831.
22. 22. Kim NK, Park YS, Heo DS, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomyein C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993, 71, 3813-3818.
23. 23. Kelsen D, Atiq OT, Saltz L, et al. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992, 10, 541-548.
24. 24. Ohtsu A, Shimada Y, Yoshida S, et al. Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG). Eur J Cancer 1994, 30A, 2091-2093.
25. 25. Louvet C, Gramont A, Demuynck B, et al. High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in poor-prognosis patients with advanced measurable gastric cancer. Ann Oncol 1991, 2, 229-230.
26. 26. Cullinan SA, Moertel CG, Wieand HS, et al. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. J Clin Oncol 1994, 12, 412-416.
27. 27. Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 1988, 22, 333-338.
28. 28. Wakui A. Phase II trial of 5′-deoxy-5-fluorouridine in the treatment of gastric cancer - a multicentre cooperative study. J Int Med Res 1988, 16, 17B-18B.
29. 29. Kurihara M, Izumi T, Yoshida S, et al. A cooperative randomized study on tegaful plus mitomyein C versus combined tegaful and uracil plus mitomyein C in the treatment of advanced gastric cancer. Jpn J Cancer Res 1991, 82, 613-620.
30. 30. Koizumi W, Kurihara M, Sasai T, et al. A phase II study of combination therapy with 5′-deoxy-5-fluorouridine and cisplatin in the treatment of advanced gastric cancer with primary foci. Cancer 1993, 72, 658-662.